Drugs / Pentavac
Pentavac
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02097472 | Apr 2014 → Dec 2015 | streptococcal pneumonia | PATH | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00366678 Background | Oct 2006 → Nov 2008 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pentavac | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00366678 ↗ |
| Known as | Diptheria Pertussis Tetanus Hep B Haemophilus b Conjugate | “Diptheria Pertussis Tetanus Hep B Haemophilus b Conjugate” NCT02097472 ↗ |
| Modality | Vaccine | “active comparator vaccines (Synflorix and Pentavac)” NCT02097472 ↗ |